Senti Biosciences is trading 11.8% lower at $0.28 now, with biotech-sector pressure the clearest available explanation. - Biotech ETF XBI is down 2.01%. - Searches found no new company-specific announcement explaining the move. - Recent biotech commentary describes cautious sentiment amid disappointing trial readouts, rising rates and investor concerns, but does not identify a direct Senti catalyst today.